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Data concerning the prognostic value of ErbB4 in breast cancer and effects on cell growth have varied in
published reports, perhaps due to the unknown signaling consequences of expression of the intracellular
proteolytic ErbB4 s80HER4 fragment or due to differing signaling capabilities of alternatively spliced ErbB4
isoforms. One isoform (Cyt1) contains a 16-residue intracellular sequence that is absent from the other (Cyt2).
We expressed s80Cyt1 and s80Cyt2 in HC11 mammary epithelial cells, finding diametrically opposed effects on
the growth and organization of colonies in three-dimensional matrices. Whereas expression of s80Cyt1 de-
creased growth and increased the rate of three-dimensional lumen formation, that of s80Cyt2 increased
proliferation without promoting lumen formation. These results were recapitulated in vivo, using doxycycline-
inducible, mouse breast-transgenic expression of s80Cyt1 amd s80Cyt2. Expression of s80Cyt1 decreased growth
of the mammary ductal epithelium, caused precocious STAT5a activation and lactogenic differentiation, and
increased cell surface E-cadherin levels. Remarkably, ductal growth inhibition by s80Cyt1 occurred simulta-
neously with lobuloalveolar growth that was unimpeded by s80Cyt1, suggesting that the response to ErbB4 may
be influenced by the epithelial subtype. In contrast, expression of s80Cyt2 caused epithelial hyperplasia,
increased Wnt and nuclear -catenin expression, and elevated expression of c-myc and cyclin D1 in the
mammary epithelium. These results demonstrate that the Cyt1 and Cyt2 ErbB4 isoforms, differing by only 16
amino acids, exhibit markedly opposing effects on mammary epithelium growth and differentiation.
Activation of the ErbB/HER/epidermal growth factor recep-
tor (ErbB/HER/EGFR) family of receptor tyrosine kinases
(RTKs) is often equated with proliferation and oncogenesis.
The family consists of four members, HER1/ErbB1/EGFR,
HER2/ErbB2/Neu, HER3/ErbB3, and HER4/ErbB4. Each
protein has a large NH2-terminal extracellular domain, a trans-
membrane domain, and a large intracellular domain with a
tyrosine-rich carboxy-terminal region and a tyrosine kinase-
like sequence (12). HER1/ErbB1, HER2/ErbB2, and HER4/
ErbB4 exhibit ligand-inducible tyrosine kinase activity,
whereas HER3/ErbB3 does not.
ErbB receptor activation at the cell surface targets multiple
cytoplasmic signaling cascades that transmit signals to the nu-
cleus. In addition to this classic RTK signaling model, ErbB
RTKs have exhibited nuclear localization (4, 17, 19, 27, 28, 37,
47, 48). While ErbB1, -2, and -3 are transported to the nucleus
as full-length receptors, one isoform of ErbB4 is cleaved upon
ligand binding, liberating the entire soluble intracellular do-
main. This intracellular, kinase-active 80-kDa cleavage product
(s80HER4) exhibits nuclear-cytoplasmic shuttling (8, 20, 25, 27).
Expression of s80HER4 mimics certain biological consequences
of ligand-induced ErbB4 expression. For example, expression
of ligand-induced ErbB4 activates the transcription factor
STAT5a in vivo and in cultured human breast cancer cells, as
does expression of s80HER4 (14, 21, 44). Inhibition of ErbB4
cleavage or its nuclear localization impairs ErbB4-mediated
STAT5a activation (25, 46, 48).
Evidence suggests that, whereas ErbB1, -2, and -3 all con-
tribute to proliferation and/or survival of the mammary epi-
thelium, ErbB4 induces specification of the mammary anlagen
through induction of LEF1 expression and is required for the
lactational differentiation of the mouse mammary gland
through activation of STAT5a (13, 38). ErbB4 expression and
activity (measured by tyrosine phosphorylation) are lowest
during phases of epithelial cell proliferation (puberty and early
pregnancy) and highest during phases of differentiation (late
pregnancy and early lactation) (35). Mammary glands from
mice that lack ErbB4 activity have lactational defects due an
impaired program of differentiation (13, 21, 44). Similarly,
impaired ErbB4 association with one of its ligands, HB-EGF,
causes lactational deficiency (53).
Studies suggests that human ErbB4/HER4 activity decreases
growth of several human breast cancer cells (7, 25, 27, 33).
However, other evidence shows that ErbB4 expression in-
creases the growth of some estrogen receptor-positive (ER)
breast cancer cells in culture (15, 22, 55). In similarity to these
cell culture studies, there are conflicting reports regarding the
prognostic value of ErbB4 expression in human breast cancers.
* Corresponding author. Mailing address: UNC Lineberger Com-
prehensive Cancer Center, University of North Carolina at Chapel
Hill, 102 Mason Farm Road, Chapel Hill, NC 27599. Phone: (919)
966-2335. Fax: (919) 966-3015. E-mail: hse@med.unc.edu.
 Published ahead of print on 13 July 2009.
4935
Many reports show that ErbB4 expression correlates with pos-
itive prognostic indicators (ER expression, lower tumor grade,
increased differentiation, lower proliferative index) and
greater disease-free and overall survival (3, 43, 45, 49, 50).
However, other reports have presented descriptions of de-
creased survival in subsets of women whose breast cancers
express nuclear ErbB4 (1, 22).
The discrepancy may stem from the different biological
properties of the ErbB4 splice variants, of which there are four
(5, 6, 16). The JMa isoform harbors a TACE cleavage site in
the extracellular domain that is required for the ligand-depen-
dent proteolysis of ErbB4 and subsequent production of
s80HER4 by -secretase (18, 27, 32); the JMb isoform lacks this
TACE cleavage site and therefore does not produce s80HER4
(6). Splice variations within the cytoplasmic domain generate
the Cyt1 and Cyt2 isoforms. Cyt1 contains a 16-amino-acid
sequence that is absent from Cyt2 (5). This Cyt1 motif harbors
potential binding sites for p85 and WW domain-containing
proteins. Signaling differences between ErbB4-Cyt1 and
ErbB4-Cyt2 have been previously reported: for example, levels
of kinase activity, protein stability, and nuclear accumulation
are greater for s80Cyt2 than for s80Cyt1 (41, 42).
We have directly compared growth and differentiation of
mammary epithelial cells expressing s80Cyt1 and s80Cyt2 in cell
culture and in vivo. HC11 cells proliferated rapidly in response
to expression of s80Cyt2 but exhibited growth inhibition in
response to s80Cyt1 expression. In three-dimensional (3D) cul-
ture experiments, s80Cyt1 expression enhanced lumen forma-
tion whereas s80Cyt2 expression resulted in the growth of large,
solid colonies. In the mouse mammary gland, inducible expres-
sion of s80Cyt1 during puberty decreased proliferation and
caused precocious lactogenesis in the ductal epithelium of vir-
gin mice. In contrast, s80Cyt2 expression resulted in epithelial
hyperplasia.
MATERIALS AND METHODS
Cell culture and transfection. HC11-pcDNA4, HC11-s80Cyt1, HC11-s80Cyt2,
HC11-s80KD, HC11-HER4, and HC11-HER4KD cells were previously described
(39). pcDNA3-HER4-P1054A cells were made in the laboratory of K. Elenius by
side-directed mutagenesis. For 3D cultures, eight-well chamber slides were
coated with growth factor-reduced Matrigel (40 l/well). A total of 5,000 cells/
well were plated in 500 l of serum-free Dubecco’s modified Eagle medium/
F12-4% growth factor-reduced Matrigel, cultured 14 days, and then fixed in 1%
paraformaldehyde–phosphate-buffered saline (1% paraformaldehyde–PBS) and
stained with DAPI (4,6-diamidino-2-phenylindole) (Vector Laboratories, Bur-
lingame, VT). Colonies were visualized using a Leica SP2 laser scanning confocal
microscope with a 63 oil numerical aperture 1.40 Plan Apo lens (Nikon). For
growth analysis, cells (0.3  106) were plated in 15-cm-diameter dishes at t  0.
Media was replaced with serum-free media at t  4 h. Three plates per cell type
per set of conditions were collected by trypsinization at 24-h intervals and
manually counted daily for 96 h. For immunocytofluorescence, cells were cul-
tured on glass slides, fixed in ice-cold methanol for 10 min, washed in PBS, and
then incubated in mouse monoclonal -catenin antibody (Sigma-Aldrich, St.
Louis, MO) diluted 1:500 in PBS. After five consecutive washes in PBS, slides
were incubated in Alexa Fluor 488-conjugated goat anti-mouse immunoglobulin
G (Molecular Probes, Invitrogen, Carlsbad, CA), washed, and mounted with
Vectashield (Vector Labs, Burlingame, VT).
Cell and tissue preparation and Western analysis. NE-PER nuclear and
cytoplasmic extraction reagents (Pierce Biotechnology, Rockford, IL) were used
to separate nuclear and cytoplasmic compartments of cells in accordance with
the manufacturer’s protocol. ErbB4 and green fluorescent protein (GFP) immu-
noprecipitations (IPs) were performed using rabbit polyclonal antibody 132 and
anti-GFP (Santa Cruz Biotechnologies, Santa Cruz, CA) as previously described
(33). Western analyses were performed as previously described (25) using PY20
antibody (Santa Cruz) directed against phosphotyrosine or anti-ErbB4 132 an-
tibody produced in our laboratory (25).
Flow cytometric analysis. Cells were collected by trypsinization and fixed in
1% paraformaldehyde. Cells were stained for terminal deoxynucleotidyltrans-
ferase-mediated dUTP-biotin nick end labeling (TUNEL) analysis using an Apo-
bromodeoxyuridine (Apo-BrdU) staining kit (Chemicon, Temecula, CA) accord-
ing to the manufacturer’s directions. For cell cycle analyses, cells were stained
with propidium iodide-RNase solution (Sigma-Aldrich) according to the manu-
facturer’s directions. Cells were analyzed using a FACScan system at the Uni-
versity of North Carolina (UNC) Lineberger Comprehensive Cancer Center
Flow Cytometry Core Facility at the UNC at Chapel Hill.
Generation and analysis of TetOp-s80Cyt1 and TetOp-s80Cyt2 mice. A 2.2-kb
cDNA fragment, encoding the entire intracellular domain of human ErbB4-Cyt1
and ErbB4-Cyt2 and tagged at the amino terminus with GFP, was subcloned into
pTRE-Tight (BD Biosciences) at the BamHI-NotI sites. The linearized trans-
gene was injected into one-cell-stage FVB mouse embryos and transplanted into
pseudopregnant females (Mouse Models Core Facility, UNC Lineberger Com-
prehensive Cancer Center). The resulting pups were screened for genomic trans-
gene insertion using primers P1 (from a human ErbB4 sequence; 5-TCC TCT
AGA GAT ATC GTC GAC AAG CTT ATC-3) and P2 (from pTRE-Tight;
5-CGG AGC ACC CTT CAG CAC CCA GAC-3). All transgenic founders
were bred to inbred FVB mice harboring the mouse mammary tumor virus-
reverse tetracycline transcriptional activator (rtTA) transgene (MTB mice) (10).
All founders transmitted the transgene to their offspring. Each resulting trans-
genic line was independently analyzed. All studies were performed using age-
matched females of the F1 or F2 generation. For timed pregnancies, mating pairs
were established and mice were monitored daily for vaginal plugs, indicating 0.5
days postcoitum (dpc). The day of partuition was designated lactation day 1 (L1).
Histological analysis and IHC. Mice were labeled for 2 h with BrdU (Sigma-
Aldrich) (10 mg/kg of body weight) by intraperitoneal injection. Mammary
glands were fixed in 10% formalin (VWR Scientific). Hematoxylin-stained whole
mounts of no. 4 (right inguinal) mammary glands were prepared as previously
described (23). Paraffin-embedded mammary glands were sectioned (in 5-m-
thick sections) and rehydrated, and immunohistochemistry (IHC) was performed
as previously described (23) using the following antibodies: GFP (1:100), from
Santa Cruz Biotechnologies, Santa Cruz, CA; phospho-Ser10 histone H3 (p-
HH3) (1:200) and cyclin D1 (1:100), both from Cell Signaling; STAT5a (1:100)
and phosphotyrosine 694 STAT5A/STAT5B (1:50), BrdU (1:500), and E-cad-
herin (1:100), all from Invitrogen-Zymed; and c-myc (1:500) and -catenin (1:
1,000), from Sigma-Aldrich. Slides were washed in PBS (pH 7.4)–0.1% Tween
20, and then staining was visualized with a Vectastain kit (Vector Laboratories,
Burlingame, VT). Cells were photographed using a Nikon FXA microscope and
Scion Image 2.0 software.
Northern analysis and RT-PCR. Total RNA was extracted using TRIzol re-
agent (Invitrogen) according to the manufacturer’s directions. Total RNA (10
g) was resolved on a 1.0% agarose-formaldehyde gel and transferred to nitro-
cellulose with 10 sodium saline citrate (Invitrogen). Membranes were hybrid-
ized with a mouse -casein cDNA probe (EcoRI fragment of EST clone 5026838;
Invitrogen, Carlsbad, CA) that was labeled with biotin by the use of a
North2South random primer labeling kit (Pierce Biotechnology, Rockford, IL).
Membranes were hybridized, washed, and developed using a North2South non-
radioactive hybridization kit (Pierce Biotechnology). Reverse transcriptase PCR
(RT-PCR) was performed as described previously (25). Primers for identification
of mouse Wnt1, mouse Wnt2, mouse Wnt5b, mouse Wnt7a, mouse Wnt10b,
mouse LEF1, and mouse GATA3 are listed in Table 1.
RESULTS
Growth inhibition of HC11 cells by expression of s80Cyt1 but
not that of s80Cyt2. We expressed GFP-tagged constructs of
s80Cyt1 and s80Cyt2 in the mouse mammary epithelial cell
(MEC)-derived HC11 cell line. Pooled clones of stably trans-
fected cells were used to compare the growth rates of HC11-
pcDNA4, HC11-s80Cyt1, HC11-s80Cyt2, and HC11-s80KD cells
(expressing kinase-dead s80Cyt1). HC11-pcDNA4 cells grew
steadily over 96 h, resulting in a 6.0-fold increase in total cell
numbers (Fig. 1A). HC11-s80Cyt1 cells grew more slowly than
HC11-pcDNA4 cells (4.2-fold increase in total cell numbers
over 96 h; P  0.011), whereas HC11-s80Cyt2 cells grew more
rapidly (9.2-fold increase at 96 h; P  0.007). Expression of
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GFP-s80Cyt1 and GFP-s80Cyt2 was observed at higher levels
than that seen with endogenous full-length ErbB4/HER4 and
s80, its endogenous proteolytic product, in HC11 cells. West-
ern analysis of HER4 IPs from cytoplasmic and nuclear
extracts demonstrated that GFP-s80Cyt2 and GFP-s80Cyt1 lo-
calized to nuclear and cytoplasmic compartments whereas
GFP-s80KD was restricted to the cytoplasm (Fig. 1C). The
requirement of kinase activity for nuclear accumulation of
s80HER4 has been previously demonstrated (8, 25, 39). We
have shown that expression of GFP-s80Cyt1 in HC11 cells re-
sults in decreased growth due to a decreased rate of cellular
proliferation (8). The intracellular domain of ErbB4 has been
reported to increase apoptosis of mammary epithelial cells
(26). To determine the effects of s80Cyt1 and s80Cyt2 overex-
pression on apoptosis in HC11 cells, we used TUNEL analysis
to detect and enumerate apoptotic cells (Fig. 1D). Expression
of GFP-s80Cyt1 resulted in a higher (threefold) increase in the
proportion of cells undergoing apoptosis (P  0.02). These
data suggest that increased cell death, combined with de-
creased cellular proliferation in response to s80Cyt1 expression,
accounts for the decrease in HC11 cell numbers in culture
under these growth conditions.
HC11 cells grow as acinar structures in three dimensions in
response to the presence of prolactin, in response to ligand-
inducible ErbB4-JMa-Cyt1 activity, and in response to the
presence of exogenous GFP-s80Cyt1 (25, 52). The latter deter-
TABLE 1. Primer sequences used for the detection of the indicated transcripts by RT-PCRa
cDNA Position (residues) Forward primer Reverse primer
Wnt1 1141–1381 AGC TGC TGC GCC TGG AGC CC GCT GAC GTG GCA AGC ACC AG
Wnt2 721–1001 AGG ACA TGC TGG CTG GCC AT TCA TAG CCT CTC CCA CAA CA
Wnt5b 1021–1171 ACA GAA CAA CGA GGC TGG CC GGC GCT GTC GTA CTT CTC CT
Wnt7 1021–1261 TCA AGA AGC CCC TGT CCT AC GCT GCA CGT GTT ACA CTT GA
Wnt10b 1201–1471 CAA CTC TGG AGC GTT CCA GC CTC TGT GAC TTT ACA CTC AT
LEF1 1561–1771 CAG CTC CTG AAA TCC CCA CC GCT GGA TGA GGG ATG CCA GT
Gata3 1441–1681 TGC AAT GCC TGC GGA CTC TA CTA GAC ATC TTC CGG TTT CG
a Primer sequences were designed from NCBI-published cDNA sequences derived from mouse genes. The residue numbers corresponding to each primer set are
shown and were used to predict the size of each amplicon. Primer sequences are shown in 5-to-3 orientation.
FIG. 1. Growth inhibition induced by s80Cyt1 and growth acceleration induced by s80Cyt2. (A) Growth analysis of HC11-pcDNA4, HC11-s80Cyt1,
HC11-s80Cyt2, and HC11-s80KD cells. Values represent average numbers of cells. Data represent values 	 standard deviations determined in three
experiments, each analyzed in duplicate. (B) HER4 IPs were subjected to Western analysis to detect total levels of HER4 and phosphotyrosine
(P-Tyr). Molecular weights are indicated to the left of each panel. IB, immunoblot. (C) HER4 IP from nuclear (represented by the letter N) and
cytoplasmic (represented by the letter C) extracts of HC11-s80Cyt1, HC11-s80Cyt2, and HC11-s80KD cells. IPs were subjected to Western blot
analysis with phosphotyrosine or ErbB4 antibodies. Nuclear and cytoplasmic extracts were subjected to Western analysis to detect -tubulin to
verify the relative purity of the cellular fractionation. (D) TUNEL analysis of cells by the use of a phycoerythrin-conjugated anti-BrdU antibody
to detect BrdU-labeled apoptotic cells. Flow cytometry was used to detect TUNEL-positive DAPI-stained cells. Quantitation of the proportion of
TUNEL-positive cells is shown. Values represent the averages of the results of three experiments, each analyzed in duplicate. Error bars represent
standard deviations.
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mination was confirmed, as shown by examination of serial
Z-plane sections of HC11-s80Cyt1 colonies (Fig. 2A). In con-
trast, HC11-s80Cyt2 colonies formed solid structures filled with
cells. By day 11 and through day 14, HC11-s80Cyt1 colonies
harbored distinct lumens surrounded by a single cell layer (Fig.
2B and C). HC11-s80Cyt2 colonies did not display lumen for-
mation at day 11 or 14 but displayed increased colony size and
numbers of cells per colony (1.95-fold more cells/colony in
HC11s80Cyt2 compared to HC11-s80Cyt1; n  30). Therefore,
expression of s80Cyt1 and s80Cyt2 impacts the structural differ-
entiation of HC11 cells with opposing outcomes.
The WW-domain binding motif is required for HER4-medi-
ated growth inhibition. Cyt1 contains a 16-amino-acid se-
quence absent from Cyt2 (5). This Cyt1 motif harbors potential
binding sites for p85 (amino acids 1056 to 1059, YXXM) and
WW domain-containing proteins (amino acids 1052 to 1056,
PPPAY). Our previous results demonstrated that overexpres-
sion of HER4-JMa-Cyt1 in HC11 cells decreased growth while
enhancing differentiation (25) and that WW-domain-contain-
ing proteins bind to the HER4 cytoplasmic domain to regulate
HER4 signaling. To determine whether the WW-domain bind-
ing motif of HER4-JMa-Cyt1 was important for HER4-medi-
ated growth inhibition, a single proline 1054-to-alanine point
mutation (termed HER4P1054A) within HER4-JMa-Cyt1 was
engineered in the laboratory of K. Elenius. This mutation
disrupts the consensus WW-domain binding motif (41, 42).
HER4-JMa-Cyt1 (referred to here as HER4), HER4P1054A,
and kinase-dead HER4-JMa-Cyt1 (referred to here as
HER4KD) were expressed by stable transfection in HC11 cells.
HER4 and HER4P1054A were detected at 185 kDa and 80 kDa,
suggesting that both of these HER4-JMa variants are able to
undergo -secretase-mediated cleavage to generate s80HER4
(Fig. 3A). HER4KD was not detected at 80 kDa, which is
consistent with previous observations that HER4-JMa requires
kinase activation and tyrosine phosphorylation prior to proteo-
lytic cleavage (39).
Growth of HC11 cells was determined after 96 h of culture
in the presence or absence of heregulin 1 (HRG), the HER4
ligand. Treatment of parental HC11 cells, but not HC11-
HER4 cells, with HRG resulted in a 1.9-fold increase in cell
numbers compared to untreated parental HC11 cell results,
which is consistent with previous determinations that increased
HER4-JMa-Cyt1 expression confers growth inhibition to
HC11 cells (Fig. 3B). In contrast, expression of HER4-P1054A
increased growth of HC11 cells under basal conditions and in
response to the presence of HRG, suggesting that this WW-
domain interaction motif may be involved in HER4-directed
growth inhibition.
In previous studies using human breast cancer cells, HER4
activation was shown to delay G2/M progression in cycling
cells. Whereas ErbB4/HER4 is endogenously expressed in
HC11 cells, we found that HRG-treated HC11 cells did not
accumulate in the G2/M phase in response to the treatment
with HRG (Fig. 3C). However, overexpression of HER4-JMa-
Cyt1 resulted in a small but significant increase in the G2/M
population under basal conditions, and the rate of increase was
further enhanced in response to treatment with HRG (Fig.
3D). G2/M accumulation was not observed in HC11 cells ex-
pressing HER4-P1054A or in cells expressing HER4KD. These
data suggest that the WW-domain binding motif may be re-
quired for HER4-meditated growth inhibition in HC11 cells, in
part through decreasing the rate of transit through the G2/M
phase.
Nuclear and cytoplasmic expression of s80Cyt1 and s80Cyt2
in the mammary epithelium in vivo. To assess the effects of
s80Cyt1 and s80Cyt2 expression on growth and differentiation of
MECs in vivo, TetOp-s80Cyt1 and TetOp-s80Cyt2 transgenes
were constructed that contained a doxycycline (DOX)-induc-
ible rtTA-dependent promoter driving expression of either
GFP-s80Cyt1 or GFP-s80Cyt2. The transgenes were injected into
one-cell-stage mouse embryos, generating four independent
transgenic founders for TetOp-s80Cyt1 and three independent
founders for TetOp-s80Cyt2 (referred to hereafter as TetOp-
Cyt1 and TetOp-Cyt2). Each transgenic founder was crossed
with mice harboring the mouse mammary tumor virus-rtTA
transgene (MTB mice) (10). DOX-inducible transgenic expres-
sion of the GFP-tagged s80Cyt1 and s80Cyt2 products was ex-
amined in 4-week-old double transgenic F1 offspring treated
for 48 h with DOX. Western analysis to detect HER4 in GFP
IPs from whole mammary extracts demonstrated DOX-induc-
ible expression of GFP-s80Cyt1 in MTB/Cyt1 mice but not in
TetOp-Cyt1 mice (Fig. 4A). Similarly, GFP-s80Cyt2 was de-
tected in DOX-treated MTB/Cyt2 but not TetOp-Cyt2 mice.
IHC detection of GFP specifically in the mammary epithelium
was detected in MTB/Cyt1 and MTB/Cyt2 mice treated with
DOX but not in vehicle-treated mice (Fig. 4B).
FIG. 2. Lumen formation in cells expressing s80Cyt1 but not s80Cyt2.
Cells were cultured in 3D-Matrigel and stained using DAPI and pho-
tographed on days 8 (A), 11 (B), and 14 (C). Arrows in panels indicate
lumen (L) formation. (A) Confocal microscopy-acquired serial
Z-plane sections through DAPI-stained colonies. A single differential
interference-contrast image is shown to the right of each series. Num-
bers in the right panels represent average numbers of cells/colony (n 
30; P  0.002 [Student’s unpaired t test]). (B and C) Single-plane
sections are shown for each colony at day 11 (B) and day 14 (C).
DAPI-staining images are at the left side of the figure; DIC images are
at the right. Scale bars, 50 m. Note that a lower magnification was
used for the s80Cyt2 image in panel C in order to visualize the entire
HC11-s80Cyt2 colony.
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The majority of the GFP MECs expressing GFP-s80Cyt1
and GFP-s80Cyt2 displayed both nuclear and cytoplasmic local-
ization of the GFP-tagged product (Fig. 4C). However, a sig-
nificantly greater amount of cells with strictly nuclear localiza-
tion was observed with GFP-s80Cyt2 compared to GFP-s80Cyt1,
which is consistent with previous reports demonstrating in-
creased nuclear localization and/or accumulation of s80Cyt2
(42).
Histologic examination of hematoxylin- and eosin-stained
mammary sections from virgin females at 6 months of age
revealed significant differences between mammary glands ex-
pressing GFP-s80Cyt1 and GFP-s80Cyt2 and vehicle-treated
controls (Fig. 4D, E, and G, showing additional images taken
from individual DOX-treated samples). In contrast to the nar-
row lumens in mammary glands of vehicle-treated mice, the
ducts of DOX-treated MTB/Cyt1 mice were distended with
secretory material that included fat globules, suggesting an
enhanced degree of lactogenic differentiation driven by GFP-
FIG. 3. The WW-domain binding motif within HER4-Cyt1 is important for HER4-mediated growth inhibition. (A) Expression of human
HER4-JMa-Cyt1, and of the P1054A point mutation that abrogates WW domain binding, in HC11 cells cultured in serum-free media and
stimulated for 30 min with HRG (10 ng/ml). Kinase-dead HER4KD harbors a Lys-to-Ala mutation within the ATP binding pocket of the kinase
domain (see Fig. 1 and references 24 and 25). Western analysis of HER4 IPs and whole-cell lysates detected total HER4 and alpha-actin,
respectively. The positions of full-length HER4 (arrows) and the s80/m80 cleavage product of HER4 (arrowheads) are indicated. Nonspecific bands
are indicated (*). Molecular weights are indicated at the right side of each panel. (B) Growth analysis of HC11, HC11-HER4, HC11-HER4
KD,
and HC11-HER4P1054A cells cultured in the presence or absence of HRG (2 ng/ml) for 96 h. A total of 105 cells were plated and were counted
96 h after plating. Values represent average numbers of cells 	 standard deviations determined in three experiments, each analyzed in duplicate.
(C) Cells were plated in media containing 10% serum and harvested 24 h after plating. Cells were stained with propidium iodide and analyzed by
flow cytometry to determine DNA content per cell. (D) Quantitation of the number of cells containing 4 N DNA. Values represent the averages
of the results of three experiments; each sample was analyzed in triplicate. Error bars indicate standard deviations.
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s80Cyt1. In contrast, mammary ducts of DOX-treated MTB/
Cyt2 mice were not distended with secretory material and
displayed thickened ductal epithelium containing multiple cell
layers and numerous mitotic figures. IHC detection of prolif-
erating cell nuclear antigen (PCNA) was increased in the duc-
tal epithelium of DOX-treated MTB/Cyt2 mice compared to
vehicle-treated controls (Fig. 4F and H, showing additional
representative images taken from individual DOX-treated
samples). PCNA was rarely found in the quiescent ductal ep-
ithelium of DOX-treated MTB/Cyt1 mice. These results sug-
gest that whereas GFP-s80Cyt1 expression confers differentia-
tion to MECs, GFP-s80Cyt2 causes hyperplasia.
Pubertal growth of the mammary epithelium is decreased by
expression of s80Cyt1 but increased by that of s80Cyt2. DOX
treatment beginning at 3 weeks of age induced transgene ex-
pression at the onset of puberty. Mammary glands were exam-
FIG. 4. Expression of s80Cyt1 decreases mammary ductal growth, but expression of s80Cyt2 increases ductal growth. (A and B) Mice (4 weeks
old) were treated with DOX for 48 h or left untreated. (A) Transgene expression was analyzed by IP of GFP followed by immunoblotting (IB)
for ErbB4. Whole mammary lysates were analyzed by IB for beta-tubulin. (B) IHC to detect GFP. Representative photomicrographs are shown.
(C) All GFP cells (10 fields/sample) were scored for GFP in the nucleus (Nuc.) or in the cytoplasm (Cyto.) or in both the nucleus and cytoplasm.
Individual data points indicate the following: [number of GFP cells in specific compartment 
 total number of GFP cells]. The midlines indicate
the average value for each group. * indicates P  0.001 (Student’s unpaired t test; n  7). (D and E) Hematoxylin- and eosin-stained mammary
glands of 6-month-old mice treated with DOX since 3 weeks of age or left untreated. The boxed areas in panel D are shown at higher magnification
in panel E. Arrows indicate filled lumens in DOX-treated MTB/Cyt1 mice. Arrowheads indicate numerous periductal blood vessels in DOX-
treated MTB/Cyt2 mice. (F) IHC detection of PCNA in 6-month-old female mice. Values shown at bottom right of each panel indicate the
percentage of the total epithelial population that stained positive for PCNA and represent the average results determined with five randomly
chosen fields from mammary gland sections derived from five mice per group examined at a magnification of 400. (G and H) Mammary glands
were harvested from virgin female mice 15 weeks of age. (G) Hematoxylin- and eosin-stained mammary gland sections obtained from mice
expressing s80Cyt1 (top row) or s80Cyt2 (bottom row) in the mammary epithelium in response to DOX treatment beginning at 3 weeks of age and
persisting until 15 weeks of age. (H) Immunohistochemical detection of PCNA in mammary sections harvested from virgin female mice treated
with DOX from 3 weeks of age until 15 weeks of age to induce expression of s80Cyt1 (upper panel) or s80Cyt2 (bottom panel).
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ined at 5 weeks of age (i.e., after 2 weeks of DOX treatment;
Fig. 5A). Whole mounted hematoxylin-stained mammary
glands of DOX-treated MTB/Cyt1 mice revealed decreased
lengthening of the ductal epithelium into the fat pad of the
developing breast compared to those of DOX-treated TetOp-
s80Cyt1 mice. In contrast, the MTB/Cyt2 ductal epithelium
advanced further than what was observed in DOX-treated
TetOp-Cyt2 mammary glands. Terminal end buds (TEBs), dis-
tal club-shaped epithelial structures, represent the most pro-
liferative compartment of the pubertal mammary epithelium.
Fewer TEBs were seen in DOX-treated MTB/Cyt1 mammary
glands, whereas more TEBs were seen in MTB/Cyt2 mice,
compared to single transgenic controls.
At 10 weeks of age, the DOX-treated MTB/Cyt1 epithelium
had not fully permeated the fat pad and displayed persistent
TEBs, unlike what was seen in DOX-treated MTB/Cyt2,
TetOp-Cyt2, and TetOp-Cyt1 mammary glands (Fig. 5B). De-
creased ductal elongation in DOX-treated MTB/Cyt1 mice was
observed in each of the four TetOp-Cyt1 transgenic mouse
lines, whereas an increased rate of ductal extension in DOX-
treated MTB/Cyt2 mice was observed with all three TetOp-
Cyt2 mouse lines. By 16 weeks of age, the mammary epithe-
lium of DOX-treated MTB/Cyt1 mice fully penetrated the fat
pad and TEBs had regressed (data not shown). We restricted
the remainder of our analysis of TetOp-Cyt1 mice to mice
derived from transgenic line 32 and of TetOp-Cyt2 mice to
transgenic line 2.
Mammary glands from aged virgin female mice (52 weeks of
FIG. 5. Epithelial proliferation increased via s80Cyt2 expression but decreased via s80Cyt1 expression. (A to C) Whole-mount hematoxylin
staining of mammary glands from DOX-treated mice at (A) 5 weeks, (B) 10 weeks, and (C) 52 weeks or later. Vertical arrows indicate TEBs at
5 weeks. Data represent average numbers of TEBs 	 standard deviations. (D to K) IHC to detect BrdU in TEBs (D to G) and ducts (H to K)
from 5-week-old mice. Epithelial cells in five random fields per sample (n  4) were scored as BrdU or BrdU. Data represent percentages of
epithelial population that were BrdU and are shown as average percentages 	 standard deviations. *, P  0.033, Student’s unpaired t test. (L
to O) Immunostaining for p-HH3 (P-histone H3) in TEBs from 5-week-old mice. Arrows indicate positive nuclei. Data indicate percentages of the
total epithelial cell population (	 standard deviations) that were p-HH3. M, metaphase DNA; A, anaphase DNA; T, telophase DNA.
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age or older) treated with DOX since 3 weeks of age were
examined by whole-mount hematoxylin staining (Fig. 5C). In-
creased numbers of lobuloalveolar (LA) buds were seen along
the ductal epithelium of the mammary glands expressing GFP-
s80Cyt1 compared to the quiescent ductal epithelium seen in
controls. Mammary glands expressing s80Cyt2 showed a re-
markable increase in epithelial density compared to single
transgenic controls, which is consistent with an elevated rate of
proliferation in the mammary epithelium due to the expression
of GFP-s80Cyt2.
Within TEBs and the ductal epithelium, expression of
s80Cyt1 decreases cellular proliferation, whereas that of s80Cyt2
increases cellular proliferation. We examined the rate of cel-
lular proliferation in DOX- and vehicle-treated MTB/Cyt1 and
MTB/Cyt2 mice at 5 weeks of age (i.e., after 2 weeks of DOX
treatment) by the use of IHC detection of BrdU incorporation
into genomic DNA. TEBs in DOX-treated MTB/Cyt1 mice
displayed a 2.6-fold reduction in BrdU incorporation com-
pared to TEBs from vehicle-treated MTB/Cyt1 mice (Fig. 5D
to G). In contrast, BrdU incorporation was increased in TEBs
from DOX-treated MTB/Cyt2 mice by 2.4-fold over TEBs in
vehicle-treated MTB/Cyt2 mice.
Within the ductal epithelium of 5-week-old mice, DOX-
treated MTB/Cyt1 mice again demonstrated decreased BrdU
incorporation versus vehicle-treated controls (Fig. 5H to K). In
contrast, the ductal epithelium of DOX-treated MTB/Cyt2 was
highly proliferative, displaying a 2.2-fold increase in BrdU in-
corporation compared to vehicle-treated controls.
Despite the decreased cellular proliferation in DOX-treated
MTB/Cyt1 samples, as measured by PCNA and BrdU levels,
an increased rate of formation of early mitotic cells was ob-
served in TEBs from DOX-treated MTB/Cyt1 mice (Fig. 5L to
O). Using p-HH3 as a mitotic marker, a threefold increase in
mitotic cell levels was seen in TEBs from DOX-treated MTB/
Cyt1 mice compared to untreated controls. Examination of
p-HH3 subnuclear patterning demonstrated that the majority
of p-HH3 appeared in a diffuse and punctate nuclear pattern in
DOX-treated MTB/Cyt1 samples, which is consistent with the
earliest stages of mitosis (prophase). In contrast, nuclei from
untreated controls showed p-HH3 patterns representing each
of the stages of mitosis (prophase, metaphase, anaphase, and
telophase). This suggests that decreased transit through early
mitosis is one reason for the delayed growth rate of MECs
expressing GFP-s80Cyt1. These data are consistent with previ-
ous reports that expression of ErbB4-Jma-Cyt1 and s80Cyt1
decreased the rate of cell cycle progression through the G2/M
phase in many, but not all, breast cancer cell lines (33, 24, 39).
Expression of s80Cyt1 but not s80Cyt2 induces STAT5a phos-
phorylation and milk gene expression in mammary glands of
virgin mice. Lipid accumulation was consistently seen in mam-
mary glands from virgin DOX-treated MTB/Cyt1 mice but not
in virgin DOX-treated MTB/Cyt2 mice (see Fig. 4). Mammary
glands from 6-month-old virgin mice (treated with DOX since
the age of 3 weeks or left untreated) were assessed for markers
of lactogenic differentiation, including STAT5a phosphoryla-
tion and nuclear localization, and expression of -casein, a
milk protein. Subcellular localization of STAT5a was examined
by IHC (Fig. 6A to D). In samples from DOX-treated MTB/
Cyt1 mice, luminal epithelial cells expressed abundant nuclear
STAT5a (Fig. 6C). DOX-treated MTB/Cyt2 mammary glands
expressed only moderate levels of STAT5a with mixed cyto-
plasmic and nuclear localization (Fig. 6D), in similarity to
vehicle-treated controls (Fig. 6A to B). In 6-month-old mice,
expression of -casein mRNA was detected in RNA samples
harvested from mammary glands expressing GFP-s80Cyt1 but
not in those from mammary glands expressing GFP-s80Cyt2 or
in those from DOX or vehicle-treated controls (Fig. 6E).
To assess whether short-term GFP-s80Cyt1 expression could
induce STAT5a activity in virgin mice, MTB/Cyt1 mice were
treated with DOX for 96 h. Phosphotyrosine 694 STAT5A/
STAT5B and -casein mRNA expression was abundant in the
mammary epithelium of DOX-treated MTB/Cyt1 mice but not
in that of vehicle-treated mice (Fig. 6F to H). Taken together,
these results suggest that expression of s80Cyt1, but not that of
s80Cyt2, is sufficient to rapidly induce some of the molecular
aspects of lactogenic differentiation in virgin mice in vivo in the
absence of hormonal signals that normally influence lactogen-
esis.
s80Cyt1 does not impair alveolar proliferation during preg-
nancy. During pregnancy, rapid cellular proliferation and dif-
ferentiation of the LA epithelium generates the milk-produc-
ing structures of the mammary gland. To determine the effects
of GFP-s80Cyt1 expression on proliferation of the LA and duc-
tal epithelium specifically during pregnancy, DOX was with-
held from mice until timed pregnancies were established in
12-week-old virgin mice. DOX treatment began at 0.5 dpc and
lasted through L10. Areas of focal hyperplasia were seen in
lactating mammary glands from DOX-treated MTB/Cyt2 mice
but not in those from DOX-treated MTB/Cyt1 mice (Fig. 6I to
L). Despite this, results with respect to differentiation of the
mammary epithelium appeared to be similar in all samples.
Control, MTB/Cyt1, and MTB/Cyt2 mammary glands dis-
played increased LA epithelial content composed of lipid-pro-
ducing secretory cells, milk-filled lumens, and few visible adi-
pocytes. MTB/Cyt1 and MTB/Cyt2 mothers were able to
successfully nurse pups through weaning (21 days). Therefore,
expression of GFP-s80Cyt1 or GFP-s80Cyt2 does not adversely
affect pregnancy-induced lactogenic differentiation of the
mammary gland, which is consistent with the proposed role of
ErbB4 in lactogenesis. However, these data also suggest that
GFP-s80Cyt1 expression did not impair pregnancy-induced pro-
liferation of the LA epithelium, in contrast to the ductal epi-
thelial cell growth inhibition observed during puberty.
To examine proliferation within specific epithelial compart-
ments (ductal versus LA) during pregnancy, PCNA expression
was examined by IHC. No statistically significant differences in
PCNA staining of the LA epithelium between samples from
vehicle-treated mice and those from DOX-treated MTB/Cyt1
mice or MTB/Cyt2 mice were observed (Fig. 7A to C and G).
However, the ductal epithelium of DOX-treated MTB/Cyt1
mice displayed fewer PCNA cells (19 out of 322 ductal cells)
compared to the ducts of vehicle-treated MTB/Cyt1 mice (56
out of 310 cells; P  0.001). In contrast, the ductal epithelium
of DOX-treated MTB-Cyt2 mammary glands displayed a dra-
matic increase in the PCNA-positive population (172/333; P 
0.001), again emphasizing the opposing effects of the presence
of Cyt2 and Cyt1 HER4 isoforms.
At L10, PCNA cells in the LA epithelium in mammary
glands from DOX-treated and vehicle-treated MTB/Cyt1 mice
were similar, again suggesting that expression of s80Cyt1 does
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not decrease growth of the LA epithelium (Fig. 7D to F and
G). However, numerous PCNA LA cells were identified at
L10 in mammary glands from DOX-treated MTB/Cyt2 mice.
Therefore, proliferative stimulation by s80Cyt2 is not limited to
the ductal epithelium. Whereas s80Cyt2 expression during preg-
nancy did not further increase proliferation in the already
highly proliferative LA epithelium, s80Cyt2 expression contin-
ued to drive cellular proliferation in cells that would normally
exit the cell cycle.
To test the cell type specificity of s80Cyt1-mediated growth
inhibition, we examined the mammary epithelium at early
pregnancy (7.5 dpc) in MTB/Cyt1 mice. DOX treatment com-
menced at 3 weeks of age, pregnancies were established at 8
weeks of age (mid-to-late puberty), and mammary glands were
harvested at 9 weeks of age (late puberty simultaneous with
early pregnancy). We compared MTB/Cyt1 mammary glands
from pregnant and pubertal mice (Fig. 7H) to MTB/Cyt1
mammary glands from virgin and pubertal mice (Fig. 7I) in
order to specifically examine ductal growth inhibition in the pres-
ence or absence of early LA development. To rule out the effects
of DOX treatment on ductal versus LA growth, pubertal and
virgin TetOp-Cyt1 siblings were also examined (Fig. 7J).
Decreased lengthening of the ductal epithelium was again
seen in DOX-treated MTB/s80 mice (see Fig. 4), regardless of
whether the mice were pregnant or virgin (Fig. 7H to J). TEBs
characteristic of the growing, pubertal ductal epithelium were
evident in mammary glands expressing GFP-s80Cyt1 but had
already regressed in control, DOX-treated TetOp-Cyt1 mice.
These data confirm that lengthening of the ductal epithelium
was impaired by expression of s80Cyt1 in both virgin and preg-
nant mice. However, even though ductal length was decreased
in pregnant DOX-treated MTB/Cyt1 mice, developing LA
structures (typical of the mammary gland during pregnancy)
were readily apparent. Therefore, expression of GFP-s80Cyt1
FIG. 6. Precocious differentiation and STAT5a activation in mammary glands expressing s80Cyt1 but not s80Cyt2. (A to D) STAT5a IHC analysis
using mammary glands from 6-month-old virgin female mice. Representative photomicrographs are shown (n  5 per group). Insets show views
at higher magnification. (E) RT-PCR of total mammary RNA harvested from mice 6 months of age. RNA samples from three mice per genotype
were pooled prior to RT-PCR to reduce mouse-to-mouse variation. Primers were used to detect mouse -casein, mouse keratin 18 (K18),
transgenic bacterial rtTA, or human ErbB4 transcripts. Human ErbB4 primers flanked the 48-bp region of s80Cyt1 that is absent from s80Cyt2 to
discriminate between the two isoforms based on amplicon size. Genotypes are indicated at the top of the panels. Samples in the last lane were
analyzed without RT (Rv.Tr.). (F and G) Phospho-Tyr694-STAT5a/STAT5b in 6-week-old virgin MTB/Cyt1 mice treated with DOX for 96 h
or left untreated. (H) Top panel: Northern analysis (using a -casein cDNA probe) of total mammary RNA from mice left untreated or treated
with DOX for 96 h. Lower panel: corresponding ethidium-stained RNA gel. Genotypes are indicated at the top of the panels. (I to L) Mice (12
weeks of age) were left untreated or treated with DOX from 0.5 dpc to L10. The arrow in panel L indicates focal hyperplasia. Representative
hematoxylin- and eosin-stained sections of mammary glands are shown.
VOL. 29, 2009 ErbB4 ISOFORMS DIFFERENTIALLY AFFECT BREAST EPITHELIUM 4943
differentially affects these two cell populations of the mammary
epithelium.
Increased -catenin signaling in mammary glands express-
ing s80Cyt2. To determine the mechanisms by which GFP-
s80Cyt2 may increase growth of MECs, we examined members
of several signaling pathways known to affect growth of the
mammary epithelium. Levels of p53 and NF-B phospho-p65
(as determined by IHC) and levels of phospho-ErbB1 and
phospho-ErbB2 (as determined by IP of each from mammary
extracts, followed by phosphotyrosine immunoblot analysis)
were unaltered in mammary glands expressing GFP-s80Cyt1 or
GFP-s80Cyt2 compared to controls (data not shown). However,
IHC revealed elevated levels of c-myc (Fig. 8A to D) and cyclin
D1 (Fig. 8E to H) in mammary glands expressing GFP-s80Cyt2
but not in mammary glands expressing GFP-s80Cyt1. Because
the genes encoding both c-myc and cyclin D1 are transcrip-
tional targets of -catenin, we examined expression and sub-
cellular localization of -catenin by IHC (Fig. 8I to L). Mod-
erate levels of -catenin were observed to have localized to the
plasma membrane in the MECs of vehicle-treated controls
(Fig. 8I to J) and DOX-treated MTB/Cyt1 mice (Fig. 8K). In
contrast, mammary glands from DOX-treated MTB/Cyt2 mice
displayed an increased intensity of -catenin staining localized
to nuclei and cytoplasm (Fig. 8L), indicating -catenin stabili-
zation in mammary glands expressing GFP-s80Cyt2.
IHC detection of E-cadherin demonstrated abundant cell
surface localization of E-cadherin in the ductal epithelium of
mammary glands harvested from vehicle-treated mice or from
DOX-treated MTB/Cyt1 mice (Fig. 8M to P). However, E-
cadherin expression was reduced in ductal epithelial cells ex-
pressing s80Cyt2.
Wnts are secreted ligands that bind to cell surface receptors,
resulting in stabilization and nuclear localization of -catenin.
Multiple members of the Wnt family (Wnt1, Wnt2, Wnt10a,
FIG. 7. Growth inhibition in the ductal epithelium but not the LA epithelium in response to expression of s80Cyt1. (A to F) PCNA IHC analysis
of mammary sections treated with DOX until 16.5 dpc or left untreated was withheld until mice were 12 weeks of age. DOX treatment began at
0.5 dpc and was maintained through 16.5 dpc (A to C) or through L10 (D to F). Ductal epithelia are indicated by outlining in panels A to C. Arrows
in panel B indicate lipid droplet formation. (G) Quantitation of the percentages of epithelial cells that were PCNA in ducts and LA at 16.5 dpc
and at L10. (H to J) Mice were treated with DOX beginning at 3 weeks of age. Pregnancy (H) was timed in specified animals beginning at 8 weeks.
Mammary glands from age-matched DOX-treated virgin or pregnant (7.5 dpc) mice were analyzed in parallel. Images represent whole-mount
hematoxylin-stained mammary glands, showing pregnancy-induced LA development in the same gland in which s80Cyt1 has retarded ductal
elongation. Boxed areas are enlarged at right to show detail. Arrows indicate location of TEBs in panels H and I and lack of TEBs in panel J.
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and Wnt7) are associated with tumorigenesis in the mammary
epithelium, whereas others (Wnt5b) are associated with differ-
entiation of the LA epithelium in response to the presence of
progesterone (51, 31). Expression of each of these ligands in
HC11 cells expressing GFP-s80Cyt1 and GFP-s80Cyt2 was ex-
amined by RT-PCR (Fig. 8Q). Increased expression of the
proliferative Wnts (Wnt1, Wnt2, Wnt7, and Wnt10b) was ob-
served in RNA from HC11-s80Cyt2 cells but was detected only
at very low levels in HC11-pcDNA4 and HC11-s80Cyt1 cells. In
contrast, Wnt5b (associated with LA differentiation) was de-
tected in HC11-s80Cyt1 cells but not in HC11-s80Cyt2 cells.
Using RNA harvested from mammary glands of virgin, DOX-
treated MTB, MTB/Cyt1, and MTB/Cyt2 mice, an increase in
the levels of transcripts encoding Wnt1, Wnt2, and Wnt10b
FIG. 8. Stabilization and nuclear localization of -catenin in cells expressing s80Cyt2 but not in cells expressing s80Cyt1. (A to P) IHC detection
of c-myc (A to D), cyclin D1 (E to H), -catenin (I to L), and E-cadherin (M to P) in mammary glands from virgin 6-month-old female mice left
untreated or treated with DOX from 3 weeks of age. Arrows indicate nuclei lacking -catenin localization. Arrowheads indicate nuclear -catenin.
(Q) RT-PCR analysis of total cellular RNA harvested from HC11-pcDNA4, HC11-s80Cyt1, and HC11-s80Cyt2 cells growing in 10% serum (left
panel) or from virgin female MTB, MTB/Cyt1, and MTB/Cyt2 mice treated with DOX for 96 h (right panel). Primers specific for the transcripts
indicated at the right of each panel were used. (R) Cells were transfected with a TCF/LEF-dependent promoter-firefly luciferase reporter and a
constitutive Renilla luciferase reporter and cultured in serum-free (SF) media or in serum-free media with 10 mM LiCl. At 48 h after transfection,
whole-cell extracts were analyzed; data represent relative light units (RLU). Values shown are normalized to numbers of relative light units per
microgram observed in untreated HC11-pcDNA4 cells. Data represent average values (	 standard deviations) determined in three experiments,
each analyzed in triplicate. (S) Immunofluorescence detection of -catenin in cells growing in media with 10% serum.
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was detected in mammary glands expressing s80Cyt2 compared
to control mammary glands (Fig. 8Q). The level of each of
these transcripts encoding the proliferative Wnts was de-
creased in mammary glands from MTB/Cyt1 mice. Wnt5b was
not detected in MTB/Cyt2 mammary glands but was readily
detected in mammary glands expressing s80Cyt1. Taken to-
gether, these data suggest that proliferative Wnts are ex-
pressed at higher levels in mammary epithelial cells expressing
s80Cyt2 but not in those cells expressing s80Cyt1.
To further assess the relative levels of -catenin-dependent
transcriptional activity in HC11 cells expressing GFP-s80Cyt1
and GFP-s80Cyt2, a -catenin reporter construct harboring a
promoter activated by transcription factors of the -catenin-
dependent TCF/LEF family was used. Increased levels of
-catenin-dependent luciferase were detected in HC11-s80Cyt2
cells compared to HC11-s80Cyt1 cells (Fig. 8R). As a positive
control for each sample, addition of LiCl was used to inhibit
GSK-3, therefore stabilizing the -catenin content. Addition
of LiCl increased luciferase activity over what was seen under
basal conditions in all samples, but the activity was again great-
est in HC11-s80Cyt2 cells. Membrane localization of -catenin
in HC11 cells and in HC11-s80Cyt1 cells was observed by im-
munocytofluorescence determinations (Fig. 8S). However,
-catenin did not display membrane localization in HC11-
s80Cyt2 cells but rather was located diffusely in the cytoplasm
and nucleus. These data, taken together, suggest that increased
Wnt signaling results in cytoplasmic accumulation and nuclear
localization of -catenin, which may increase growth of cells in
response to GFP-s80Cyt2.
DISCUSSION
Despite extensive studies into the role and the prognostic
value of ErbB receptors in breast cancer, the significance of
ErbB4 has remained unresolved (9), partly due to its unique
biology within the ErbB family as a cytoplasmic and nuclear
signaling molecule and partly due to the splice variations of
ErbB4 which increase the complexity of ErbB4 signaling out-
comes (15, 16, 41, 42, 54). We have developed cell culture and
mouse models to compare directly the effects of the two cyto-
plasmic ErbB4 isoforms on development and homeostasis of
MECs. Alternative splicing generates these two naturally oc-
curring isoforms, both of which have been previously detected
in normal human mammary tissue, clinical breast cancer spec-
imens, and breast cancer cell lines. Although they differ from
each other by only 16 amino acids, expression of one isoform
(s80Cyt1) results in a phenotype that is diametrically opposed to
the phenotype produced by the other (s80Cyt2).
Expression of s80Cyt1 results in profound growth inhibition
and precocious differentiation of the ductal epithelium (Fig. 4
and 7). The ability of s80Cyt1 to inhibit growth and enhance
differentiation of MECs may explain why ErbB4 expression
correlates with a more favorable prognosis in many breast
cancer studies. Data presented here demonstrate that one as-
pect of ErbB4 signaling, the production of s80Cyt1, is sufficient
to initiate some of the molecular aspects of lactogenic differ-
entiation in the absence of the hormonal signals of pregnancy.
Additionally, this is the first demonstration that s80Cyt1 is far
more potent in inducing differentiation than s80Cyt2. In the
models tested, in fact, s80Cyt2 had little or no effect on differ-
entiated gene expression. This was seen in vivo, as well as in 3D
HC11 cultures, in which expression of s80Cyt1 resulted in the
formation of lumen-containing acinar structures, a process that
has previously been shown to require JAK2 and STAT5a ac-
tivity (52). In contrast, expression of s80Cyt2 in HC11 cells
resulted in the organization of solid epithelial spheres harbor-
ing an increased number of cells. The reasons for differential
structural organization due to s80Cyt1 versus s80Cyt2 expression
are not obvious at this point, especially in light of reports that
STAT5a phosphorylation (but not transcriptional activation) is
induced by expression of either s80Cyt1 or s80Cyt2 in serum-
starved cells (25, 42). Increased levels of E-cadherin in s80Cyt1-
expressing cells (Fig. 6) or in those expressing ErbB4-JMa-
Cyt1 (33) may promote epithelial polarization and adherens
junction formation, both of which are required for lumen for-
mation. Interestingly, STAT5a activation is known to stabilize
E-cadherin accumulation at the cell surface, promote homo-
typic cell-cell adhesion, and stabilize -catenin–E-cadherin in-
teractions in breast epithelial cells in culture (40). Given that
s80Cyt1 promotes STAT5a activation to a greater degree than
does s80Cyt2, it is possible that the s80Cyt1-STAT5a complex
functions in epithelial cells to enhance E-cadherin accumula-
tion at the cell surface. Another hypothesis is that a certain
level of growth inhibition in response to s80Cyt1 expression
primes the mammary epithelium for lumen formation or lac-
tational differentiation in a STAT5a-dependent manner. Con-
versely, the proliferative capacity of MECs expressing s80Cyt2
may prevent STAT5a-mediated differentiation in the absence
of pregnancy-induced hormones.
Intriguingly, growth inhibition via expression of s80Cyt1 was
limited to the ductal epithelium of the mammary gland, as
expression of s80Cyt1 at an equivalent level did not decrease
growth of LA structures during pregnancy. This observation
highlights a cellular specificity of s80Cyt1-mediated growth in-
hibition within the mammary epithelium and underscores the
idea that, despite the common origin of these two epithelial
populations, the biology of each is unique. This also demon-
strates that the level of DOX-induced s80HER4 expression has
specific rather than general effects; that is, it does not result in
growth inhibition in all cell populations.
In direct contrast to s80Cyt1-mediated differentiation, s80Cyt2
expression results in epithelial hyperplasia, with increased ex-
pression and nuclear localization of -catenin, a protein in-
volved in both cellular adhesion (when associated with the
E-cadherin–actin complex found at adherens junctions) and
tumor progression (reviewed in reference 31). Cytosolic
-catenin, resulting from the disruption of -catenin–E-cad-
herin interactions, is rapidly degraded in quiescent cells.
Growth factor signaling can stabilize free -catenin, which
translocates to the nucleus, binds TCF/LEF transcription fac-
tors, and induces the expression of target genes, including
c-myc and cyclin D1. As is consistent with this model of -cate-
nin signaling, mammary glands expressing s80Cyt2 also showed
increased levels of cyclin D1 and c-myc. Interestingly, studies
have shown that the ErbB receptors EGFR/ErbB1 and ErbB2
can induce tyrosine phosphorylation of -catenin, destabilizing
the -catenin–E-cadherin interaction while increasing invasion
and metastasis in breast cancer cell lines (11, 30, 34, 36).
Although these studies focused primarily on ErbB1 and -2,
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they indicate that certain members of the ErbB receptor kinase
family cooperate with -catenin in tumorigenesis.
Interestingly, ErbB4-JMa-Cyt2 was overexpressed in a sub-
set of human breast cancer specimens (22), supporting the
notion that s80Cyt2 may confer a growth advantage to human
tumor cells. To determine the potential prognostic information
and therapeutic consequences of the presence of Cyt2 and
Cyt1 in cases of human breast cancer, it will be important to
understand the mechanism by which each ErbB4 isoform acts.
ErbB4 isoform Cyt2 lacks the 16-amino-acid insert and has the
proliferative signaling capacity described above. The 16-amino-
acid insert provides Cyt1 with at least two signaling motifs: (i)
phosphorylation at Y1056 yields a PI3 kinase interaction site
(5), and (ii) residues 1052 to 1056 (PPPAY) bind WW domain-
containing proteins (1, 2). Several WW domain-containing
proteins, including the transcription factor YAP and Wwox, a
known tumor suppressor protein that has been found to be
deleted in many cases of breast cancer, have been shown to
interact with s80HER4. Wwox expression in breast cancer has
recently been correlated with a more favorable prognosis and
with expression of membrane-bound ErbB4 (1). The stability
and perhaps signaling of the isoforms may be altered by Itch
and WWP1, another WW domain-containing E3-ubiquitin li-
gase that displays stronger binding and degradation activity
toward s80Cyt1 than toward s80Cyt2 (7, 29, 41). How these and
other interactions lead to the unique Cyt1 actions remains to
be determined.
In summary, while the in vitro and in vivo models using
s80Cyt1 and s80Cyt2 show levels of expression that are higher
than endogenous levels, the multiple data sets clearly define
ErbB4 pathways as either growth inhibitory or growth enhanc-
ing, depending upon the isoform and the cell type in which
ErbB4 is expressed. Given the complexity of ErbB4 isoform
biology, the lack of uniformity in published results regarding
ErbB4 action, and the clinical significance of ErbB4, it will be
important to develop methods to identify each isoform in clin-
ical specimens and to understand the prognostic value of
ErbB4 in the context of isoform specificity.
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